FDA seeks public input on whether cannabis, CBD should be descheduled
(This is an abridged version of a story that appears at Hemp Industry Daily.)
As the cannabis plant awaits a high-stakes review from international health authorities, the U.S. Food and Drug Administration (FDA) is asking the public to weigh in on whether cannabis, CBD and other cannabis extracts should be declassified as a controlled substance.
The United Nations’ World Health Organization (WHO) made a preliminary announcement in December that CBD has a low potential for abuse and shouldn’t be scheduled as a controlled substance.
The health agency delayed the final decision until June, when the agency will review “cannabis and cannabis resin, extracts, and tinctures of cannabis.”
As a member of the UN, the United States will forward the public comments it receives on cannabis scheduling to the agency.
Comments are due April 23